Focused On-demand Library for Ly-6/neurotoxin-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P0DP58

UPID:

LYNX1_HUMAN

Alternative names:

Endogenous prototoxin LYNX1; Testicular tissue protein Li 112

Alternative UPACC:

P0DP58; A0A140VJN6; D3DWI7; G3XAC2; Q86SR0; Q9BZG9

Background:

Ly-6/neurotoxin-like protein 1 (LYNX1), also known as Endogenous prototoxin LYNX1 and Testicular tissue protein Li 112, plays a crucial role in modulating nicotinic acetylcholine receptors (nAChRs). It influences nAChR trafficking, cell surface expression, and single channel properties, thereby affecting neurophysiological processes.

Therapeutic significance:

Understanding the role of Ly-6/neurotoxin-like protein 1 could open doors to potential therapeutic strategies. Its ability to modulate nAChR activity and prevent excessive excitation suggests a promising avenue for neurodegenerative disease intervention.